Tests vortioxetine for thinking problems in people recently diagnosed with schizophrenia
Tests vortioxetine alongside usual care in adults recently diagnosed with schizophrenia.
Key facts
- Who runs it
- Fundacion Para La Gestion De La Investigacion En Salud De Sevilla
- Where
- Sevilla, SpainSee the site
- Registry title
- Clinical trial to study the effect of an already authorized drug on other pathologies by administering it to people with a recent diagnosis of schizophrenia.
- Status
- Recruiting
- Phase
- Phase 2/3
- People taking part
- 37 people, planned
- Started
- 2 Dec 2024
- Planned end
- 6 Jul 2025
- Type of study
- Interventional
- Record updated
- 6 March 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adult outpatients with a recent diagnosis of a schizophrenia spectrum disorder who are on stable antipsychotic medicine. It tests whether adding vortioxetine helps thinking skills.
- Age
- Over 18 up to 50 years old (the registry also lists a maximum age of 64 years).
- Sex
- All sexes. Women must agree not to try to become pregnant and must use highly effective contraception.
- Disease stage
- Schizophrenia spectrum disorder confirmed by a structured interview (DSM - SCID). Negative symptom score above 14 on the PANSS scale, with at least two items at level 4 or more. Positive symptom score of 14 or less, with no more than one item at level 4 or more. Depression score (HAMD-17) of 12 or less. Must be an outpatient.
- Earlier treatment
- Stable dose of a second generation antipsychotic (not clozapine) for at least 4 weeks. No antidepressant for at least 8 weeks before randomization.
Main reasons for not taking part
- Taking an antidepressant that cannot be stopped at least 8 weeks before randomization
- Brain structure disease, organic mental disorder, or neurological disorder
- Intellectual disability with an estimated IQ below 70
- Current substance abuse or dependence, or serious risk of suicide
- Pregnant or breastfeeding, thyroid conditions, or past intolerance or failure of vortioxetine
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- Outpatient 2. Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders (DSM - SCID) diagnosis of Schizophrenia spectrum disorders. 3. Age >18-50 years old 4. Stable antipsychotic medication doses during at least 4 weeks ( all second generation antipsychotics excluding clozapine). 5. No antidepressant treatment for at least 8 weeks prior to randomization. 6. PANSS Negative subscore >14 with at least two of the items at a level >/=4 (moderate) 7. PANSS Positive subscore </=14 with not more than one of the items at a level >/=4 (moderate) 8. Hamilton Depression Rating Scale (HAMD-17) total score </=12 9. Simpson Angus Score of any item <2 10. Behaviorally Anchored Rating Scale (BARS) of any item </= 1 11. Competent and willing to sign informed consent 12. The patient, if a woman, must: agree not to try to become pregnant during the study and use adequate, highly effective contraception
Who cannot take part
- Patients taking any antidepressant and its use cannot be discontinued at least 8 weeks prior to randomization. 2. Structural brain disease (based on previous medical records) 3. Cognitive disability by history and estimated intelligence quotient (IQ) <70 (ID DSM-5 diagnosis). 4. Any serious chronic medical illnesses that may interfere with the patient's ability to comply with the study procedures or that will interfere with cognition. 5. Organic mental disorders, or mental disorders due to a general medical condition. Any neurological or neurodegenerative disorders. 6. Any current diagnosis of substance abuse or dependence. 7. Serious risk of suicide. 8. Patients with thyroid conditions. 9. Intolerance to or inefficacy of vortioxetine in the past. Patients who had failed treatment with vortioxetine were also excluded. 10. Pregnant or breastfeeding female
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 64 years old?
Where in Spain
- University Hospital Virgen Del Rocio S.L.Sevilla, SpainTaking people
About the trial
What the trial wants to find out
Primary objective: To assess the effectiveness of Vortioxetine vs. TAU in the treatment of cognitive impairments in early psychosis, measured by the change From Baseline to Week 24 in Brief Assessment of Cognition in Schizophrenia (BACS App) scores using the Composite Z-score Defined as the Weighted Sum of the Individual Patient Z-scores. [Time Frame: Baseline, week 24, week 26 and week 50]
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- Cognitive effects of adjuntive Vortioxetine in early Schizophrenia
- Plain-language title
- Tests vortioxetine for thinking problems in people recently diagnosed with schizophreniaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Fit questions
- Built from 2024-519778-38-00, who can take part
- Record updated
- 6 March 2025